Apellis Pharmaceuticals’ (APLS) stock has jumped more than 25% year-to-date based on FDA approval for treating geographic atrophy. Despite the breakthrough, the company’s ability to scale up production remains a…
About The Author
1 Medical Stock You Shouldn’t Touch With a 10-Foot Pole
